This is a preview of subscription content, log in via an institution to check access.
Reference
Bretoni A, et al. HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer. ClinicoEconomics and Outcomes Research 11: 283-300, 16 Apr 2019. Available from: URL: https://doi.org/10.2147/CEOR.S189436
Rights and permissions
About this article
Cite this article
Enzalutamide vs abiraterone acetate in prostate cancer. PharmacoEcon Outcomes News 827, 13 (2019). https://doi.org/10.1007/s40274-019-5851-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5851-4